Zobrazeno 1 - 10
of 31
pro vyhledávání: '"G. A. Shakaryants"'
Autor:
F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, D. A. Yatsenko, А. V. Emelianov, A. S. Lishuta, N. V. Khabarova, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 3, Pp 408-413 (2021)
Aim. To study the level of serum biomarkers of endothelial dysfunction and myocardial stress in patients with various types of hypertrophic cardiomyopathy (HCM).Material and Methods. 48 patients with hypertrophic cardiomyopathy (27 men and 21 women)
Externí odkaz:
https://doaj.org/article/ba9f82e067fd4a27bdea76adb8b2bd79
Autor:
F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 21, Iss 3 (2022)
Aim. To assess the relationship between fibrosis markers and structural and functional parameters in patients with various types of hypertrophic cardiomyopathy (HCM).Material and methods. This prospective comparative non-randomized study included 49
Externí odkaz:
https://doaj.org/article/88221651038545c98eec9fc4c8b2acc1
Autor:
Yu. A. Danilogorskaya, E. A. Zheleznykh, E. A. Privalova, Yu. N. Belenkov, A. A. Shchendrigina, M. V. Kozhevnikova, G. A. Shakaryants, V. Y. Zektser, A. S. Lishuta, I. S. Ilgisonis
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 15, Iss 3, Pp 328-334 (2019)
Aim. To study some vascular remodeling markers in hypertensive patients depending on the presence of type 2 diabetes mellitus.Material and methods. The study included patients with essential hypertension 1-2 degrees of increase in blood pressure with
Externí odkaz:
https://doaj.org/article/8599c7d6eda940c19466709b6e680653
Autor:
Yu. N. Belenkov, E. V. Privalova, V. Y. Kaplunova, V. Y. Zektser, N. N. Vinogradova, I. S. Ilgisonis, G. A. Shakaryants, M. V. Kozhevnikova, A. S. Lishuta
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 5, Pp 757-764 (2018)
Obesity is one of the leading and the most serious risk factors of cardiovascular diseases. Overweight provokes many metabolic and hemodynamic disorders. About 30% of inhabitants of the planet have overweight and prevalence of obesity increases by 10
Externí odkaz:
https://doaj.org/article/a2678771da9b4894a1eb1dc5551db2f1
Autor:
Yu. N. Belenkov, E. V. Privalova, V. Yu. Kaplunova, I. S. Chekneva, Yu. I. Najmann, M. V. Kozhevnikova, G. A. Shakaryants, A. S. Lishuta
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 12, Iss 5, Pp 522-527 (2016)
Aim. To study the structure of co-morbidities, especially connective tissue undifferentiated dysplasia syndrome (CTDS), in patients with hypertrophic cardiomyopathy (HCM) to develop an algorithm of complex examination of patients.Material and methods
Externí odkaz:
https://doaj.org/article/4a2701549ca14926a20f0024444ae989
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 12, Iss 1, Pp 73-79 (2013)
One of the clinical scenarios of hypertrophic cardiomyopathy (HCMP) is sudden cardiac death (SCD). The stratification of SCD risk is the key component of defining the therapeutic strategy in HCMP patients. Timely preventive treatment is the only life
Externí odkaz:
https://doaj.org/article/5d3f4a7ea6bf4cd5bc5db4ffa454fa02
Autor:
E. V. Privalova, G. A. Shakaryants, A. S. Lishuta, N V Khabarova, V. Yu. Kaplunova, D. A. Yatsenko, F. M. Bogatyreva, M V Kozhevnikova, А. V. Emelianov, Yu N Belenkov
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 3, Pp 408-413 (2021)
Aim. To study the level of serum biomarkers of endothelial dysfunction and myocardial stress in patients with various types of hypertrophic cardiomyopathy (HCM).Material and Methods. 48 patients with hypertrophic cardiomyopathy (27 men and 21 women)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ab0be5052e4b753713270496c4abf6
https://doi.org/10.20996/1819-6446-2021-06-06
https://doi.org/10.20996/1819-6446-2021-06-06
Autor:
A. S. Lishuta, V. Yu. Kaplunova, E O Korobkova, Yu N Belenkov, G. A. Shakaryants, M V Kozhevnikova, E. V. Privalova
Publikováno v:
Kardiologiia. 60:120-129
This review presents major directions in studies of myocardial hypertrophy from the aspect of transcriptomics and metabolomics. Understanding of trigger mechanisms of myocardial hypertrophy will permit transition from basic studies to individualized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c0f72ea67f1bf559ffc24ab550e79c3
https://doi.org/10.18087/cardio.2020.4.n1063
https://doi.org/10.18087/cardio.2020.4.n1063
Autor:
Yu N Belenkov, Yu Yu Kirichenko, D. A. Budanova, N V Khabarova, K. V. Lobastov, G. A. Shakaryants
Publikováno v:
Kardiologiia. 60:71-79
Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a5273747d652a213bd3c80511dd3f0
https://doi.org/10.18087/cardio.2020.3.n904
https://doi.org/10.18087/cardio.2020.3.n904
Autor:
Yu A Danilogorskaya, G. A. Shakaryants, A. S. Lishuta, Yu N Belenkov, E A Zheleznykh, N V Khabarova, E A Privalova, A A Shchendrigina, M V Kozhevnikova, V Yu Zektser
Publikováno v:
Kardiologiia. 60:4-9
Objective Investigate the dynamics of morphological and functional markers of vascular remodeling in patients with arterial hypertension (AH), including those with concomitant type 2 diabetes mellitus (DM2), during 12-month administration of perindop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b25589d0c3269318661a90dc922d92
https://doi.org/10.18087/cardio.2020.1.n888
https://doi.org/10.18087/cardio.2020.1.n888